Home

Armen Shanafelt

CIK 1656151 · last filed 2022-06-10

Armen Shanafelt is a corporate insider who has filed 22 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for SURF, was dated Jun 10, 2022. Across all open-market trades the lifetime net is +$15.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $213.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$213.64M

Companies

4

Total Filings

22

Lifetime Open-Market Net

$15.29M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Surface Oncology, Inc. (SURF) Delisted Director 3,181,817 $1.07 $3.40M $3.99M 7 2022-06-10
Spyre Therapeutics, Inc. (AGLE) Delisted Director 135,315 $12.01 $1.63M $549.7K 8 2022-06-09
Rein Therapeutics, Inc. (ALRN) Delisted Director 42,249 $2.11 $89.1K $3.75M 3 2018-06-25
PTGX Director 1,516,149 $140.91 $213.64M $7.00M 4 2018-06-12

Recent Filings

22 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-06-10 Surface Oncology, Inc. (SURF) Delisted Grant (A) — $0 EDGAR
2022-06-09 Spyre Therapeutics, Inc. (AGLE) Delisted Grant (A) — $0 EDGAR
2021-12-13 Spyre Therapeutics, Inc. (AGLE) Delisted Buy (P) +150,000 $549.7K EDGAR
2021-06-10 Surface Oncology, Inc. (SURF) Delisted Grant (A) — $0 EDGAR
2021-06-09 Spyre Therapeutics, Inc. (AGLE) Delisted Grant (A) — $0 EDGAR
2020-06-12 Surface Oncology, Inc. (SURF) Delisted Grant (A) — $0 EDGAR
2020-06-10 Spyre Therapeutics, Inc. (AGLE) Delisted Grant (A) — $0 EDGAR
2019-10-03 Surface Oncology, Inc. (SURF) Delisted Grant (A) — $0 EDGAR
2019-07-02 Surface Oncology, Inc. (SURF) Delisted Grant (A) — $0 EDGAR
2019-06-07 Spyre Therapeutics, Inc. (AGLE) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 22
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.